BioPharmSignal logoBioPharmSignal

Company Profile

Pharvaris Stock Price, News & Catalysts

Ticker:
PHVS
Exchange:
NASDAQ
Sector:
Biopharma
Location:
Netherlands

Stock performance

36.46 USD (+5.93%)

Close

Last updated: August 12, 2026

2.03B USD

Market cap

Why the stock is moving

Following the latest company update, “Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update”, PHVS closed up 5.93% at $36.46 on Aug 12, 2026. The move occurred in the trading session associated with this earnings update.

Company overview

Oral Bradykinin Therapeutics

Pharvaris develops deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist for hereditary and acquired angioedema.

On-Demand Formulation

Immediate-release deucrictibant is intended to treat acute hereditary angioedema attacks with an oral alternative to injectable therapies.

Prophylactic Formulation

Extended-release deucrictibant is designed for prevention of attacks, allowing the same molecule to address both acute and chronic treatment.

Future catalysts

  • An NDA submission for immediate-release deucrictibant in on-demand hereditary angioedema treatment is planned for the first half of 2026.
  • Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.

Recent news

  1. 01

    Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

  2. 02

    Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

  3. 03

    Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

  4. 04

    Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

  5. 05

    Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

ACAD

ACADIA Pharmaceuticals Inc.

ALXN

ALXN

ANIP

ANI Pharmaceuticals

AVRO

AVROBIO

ABEO

Abeona Therapeutics

AGLE

Aeglea Biotherapeutics

AGIO

Agios Pharmaceuticals, Inc.

ALNY

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

What is the current stock price of Pharvaris (PHVS)?

Pharvaris (PHVS) most recently closed at 36.46 USD, a +5.93% move versus the previous session.

What is the market cap of Pharvaris (PHVS)?

Pharvaris currently has a market capitalization of 2.03B USD on BioPharmSignal.

What does Pharvaris do?

Oral Bradykinin Therapeutics Pharvaris develops deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist for hereditary and acquired angioedema. On-Demand Formulation Immediate-release deucrictibant is intended to treat acute hereditary angioedema attacks with an oral alternative to injectable therapies. Prophylactic...

On which exchange is PHVS stock listed?

Pharvaris (PHVS) is associated with NASDAQ, Netherlands, Biopharma.

What is CHAPTER-3?

Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.

Which conditions is Pharvaris targeting with CHAPTER-3?

Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.

How does Pharvaris describe recent progress with CHAPTER-3?

Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.

What is Oral?

Oral Bradykinin Therapeutics Pharvaris develops deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist for hereditary and acquired angioedema.